Parrish Jay 4
4 · Vir Biotechnology, Inc. · Filed Feb 2, 2021
Insider Transaction Report
Form 4
Parrish Jay
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2021-02-01$1.49/sh+2,314$3,436→ 224,536 total - Sale
Common Stock
2021-02-01$69.91/sh−6,944$485,424→ 222,222 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-01−4,630→ 41,666 totalExercise: $1.57Exp: 2028-07-19→ Common Stock (4,630 underlying) - Exercise/Conversion
Common Stock
2021-02-01$1.57/sh+4,630$7,292→ 229,166 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-01−2,314→ 13,889 totalExercise: $1.49Exp: 2027-10-05→ Common Stock (2,314 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.
- [F2]1/4 of the shares subject to the stock option vested and became exercisable on April 3, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.
- [F3]1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.